Incidence of side-effects associated with high-dose ferric gluconate in patients with severe chronic renal failure

Nephrology

Volumn 8, Issue 1, 2003, Pages 8-10

  Bastani, Bahar ^a   Jain, Anil ^a   Pandurangan, Gopal ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaemia; Chronic renal failure; Dialysis; Ferric gluconate; Ferrlecit; Iron deficiency

Indexed keywords

FERRIC GLUCONATE; FERRITIN; HEMOGLOBIN; IRON; IRON DEXTRAN; SUCROSE; TRANSFERRIN;

ADULT; AGED; ARTICLE; CHILL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPOTENSION; MALE; NAUSEA; PRIORITY JOURNAL; SYNCOPE; TREATMENT PLANNING; VOMITING;

ADULT; AGED; ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 0037326835     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1797.2003.00118.x     Document Type: Article

References (22)

1. Nissenson AR. National cooperative rHuEPO study in patients with chronic renal failure: a phase IV multicenter study. Am. J. Kidney Dis. 1991; 18 (Suppl. 1): 24-33.
2. Kleiner MJ, Van Wyck DB, Kaupke CJ, Kirlin LF. The role of iron and other factors in patients unresponsive to EPO therapy. Semin. Dial. 1994; 7: 288-92.
3. Wingard RL, Parker RA, Ismail N, Hakim R. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am. J. Kidney Dis. 1995; 25: 433-9.
4. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998; 79: 299-305.
5. Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin. Nephrol. 1997; 48: 34-40.
6. Appendix III. Use of intravenous iron in patients receiving erythropoietin. Nephrol. Dial. Transplant. 1999; 14 (Suppl. 5): 35-6.
7. Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J. Am. Soc. Nephrol. 1998; 9: 664-8.
8. National Kidney Foundation Study Group. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am. J. Kidney Dis. 1997; 30 (Suppl. 3): S192-237.
9. Silverberg DS, Iaina A, Peer G et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am. J. Kidney Dis. 1996; 27: 234-8.
10. Fishbane S, Ungureanu V, Maesaka J, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am. J. Kidney Dis. 1996; 25: 529-34.
11. Paull J. A prospective study of dextran-induced anaphylactoid reactions in 5745 patients. Anaesth. Intensive Care 1987; 15: 163-4.
12. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical practice. JAMA 1980; 243: 1726-31.
13. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am. J. Kidney Dis. 1999; 33: 471-82.
14. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am. J. Kidney Dis. 1999; 33: 464-70.
15. Lange R, Diamant M, Marx JJM. Parenteral administration of iron: Possibilities and risks. Pharmaceutisch Weekblad 1997; 132: 103-11.
16. Pascual J, Teruel JL, Liano F, Sureda A, Ortuna J. Serious adverse reactions after intravenous ferric gluconate. Nephrol. Dial. Transplant. 1992; 7: 271-2.
17. Zanen AL, Adriaansen HJ, van Bommel EFH, Posthuma R, deJong GMTh. Oversaturation of transferrin after ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol. Dial. Transplant. 1996; 11: 820-4.
18. Navarro JF, Teruel JL, Liano F, Marcen R, Ortuno J. Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body stores in hemodialysis patients. Am. J. Nephrol. 1996; 16: 268-72.
19. Navarro JF, Teruel JL. Sodium ferric gluconate and iron requirements in hemodialysis patients. Clin. Nephrol. 1997; 48: 202.
20. Baker E, Morgan H. Iron transport. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron Metabolism in Health and Disease. Saunders, London, 1994; 63-86.
21. Aruoma OI, Kaur H, Halliwell B. Oxygen free radicals and human diseases. J. R. Soc. Health 1991; 111: 172-7.
22. Ward PA, Warren JS, Till GO, Varani J, Johnson KJ. Modification of disease by preventing free radical formation: a new concept in pharmacological intervention. Bailliere's Clin. Haematol. 1989; 2: 391-402.